Leonard JP, May WS, Ihle JN, Pettit GR, Sharkis SJ. Regulation of hematopoiesis IV: The role of interleukin-3 and bryostatin in the growth of erythropoietic progenitors from normal and anemic W/Wv mice. Blood, 1988;72:1492-1496;

Sharkis SJ, Leonard JP, Ihle JN, May WS. The effects of interleukin-3, bryostatin and thymocytes on erythropoiesis. NY Acad Sci,1989;554:59-65;

Moore MAS, Leonard JP, Flasshove M, Bertino J, Gallardo H, Sadelain M. Gene therapy - the challenge for the future. Annals of Oncology,1996;7(S2):53-58;

Flasshove M, Banerjee D, Leonard JP, Mineishi S, Li M.-X, Bertino JR. and Moore MAS. Retroviral transduction of human CD34+ umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA. Human Gene Therapy, 1998;9:63-71;

Leonard JP and Coleman M. Primary non-Hodgkin's lymphoma of bone. Cancer Investigation, 1998;16:616-617;

Coleman M. Kauffmann T, Nisce LZ, Leonard JP. Treatment of non-laparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation. International Journal of Radiation Oncology, Biology and Physics, 2000;46:1235-1238;

Flasshove M, Leonard JP, Bardenheuer W, Moore MAS. Increased resistance and selection in paclitaxel for peripheral blood progenitor cells following transduction with the MDR1 gene. TumorDiagnostik and Therapie (German), 2000; 21:51-58;

Coleman M, Leonard JP, Schuster MW, Kaufman TP. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma. Eur J Haematol 2001;66(S1):41-45;

Leonard JP, Schattner EJ, Coleman M. Biology and treatment of mantle cell lymphoma, Curr Opin Oncol, 2001, 13:342-347;

Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard JP, Fehrenbacher L,Lister TA, Stagg RJ, Tidmarsh GF, Knox SJ, Vose JM. Pivotal study of BexxarT (Iodine I 131 Tositumomab) for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas, J Clin Oncol, 2001 Oct 1;19(19):3918-28;

Leonard JP. Epratuzumab (hLL2, anti-CD22) immunotherapy of non-Hodgkin's Lymphoma. Hematologica, 2001, 86(S1):80-83;

Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J. Immunotherapy of Non-Hodgkin's Lymphomas, Hematology (Am Soc Hematol Educ Program), 2001 Jan:221-40;

Leonard JP and Link BK. Immunotherapy of NHL with Epratuzumab (anti-CD22) and Hu1D10, Semin Oncol, 2002, 29(1S2), 81-86;

Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJComparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma, Cancer, 2002, 94(4), 879-88;

Coleman M, Leonard J, Lyons L, Pekle K, Nahum K, Pearse R, Niesvizky R and Michaeli J. BLT-D (clarithromycin [biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom'smacroglobulinemia, Leuk Lymph, 2002;43(9):1777-1782;

Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after one cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease, J Nucl Med, 2002;43(8):1018-1027;

Coleman M, Leonard J, Lyons L, Szelenyi H, Niesvizky R. Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol, 2003;30(2):270-274.1;

Leonard JP, Siegel JA, Goldsmith SJ. Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: Implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma, Cancer Invest, 2003;21(2):241-252;

Siegel AB, Goldenberg DM, Cesano A, Coleman M, Leonard JP. CD22-directed monoclonal antibody therapy for lymphoma, Semin Oncol, 2003; 30(4):457-464;

Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, Elliott G, Thomas J, Ferbas J, Kern B, Briddell R, Leonard JP, Cesano A. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties, Clin Cancer Res, 2003; 9(10):3982S-3990S;

Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Cesano A, Goldenberg DM. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma, J Clin Oncol, 2003:21(16):3041-3059;

Coleman M, Goldenberg DM, Siegel AB, Ketas JC, Fiore JM, Leonard JP. Epratuzumab: Targeting B-cell malignancies through CD22, Clin CancerRes, 2003;9(10):2991S-3994S.;

Books, Chapters, Reviews:

Leonard JP and Silverstein RL. "Corticosteroids in hematologic diseases". Chapter 28 in Principles of Corticosteroid Therapy, eds. Lin AN and Paget S. Chapman and Hall, New York, NY. (in press);

Leonard JP, Petryk M, Grossbard ML. "Monoclonal antibody therapy of lymphoma". Chapter 18 in American Cancer Society Atlas of Clinical Oncology, Malignant Lymphomas, ed. Grossbard ML, BC Decker (in press);

Leonard JP and Coleman M. "Non-Hodgkin's Lymphoma", Conn's Current Therapy,ed. Rakel RE, Lippincott Williams and Wilkins, Philadelphia (in press);

Abstracts:

Leonard, J.P., Bellis, M., Ihle, J.N., May, W.S., Sensenbrenner, L.L., Sharkis, S.J. Effect of Purified Natural Interleukin-3 (IL-3) on In Vitro and In Vivo Growth of Hematopoietic Progenitor Cells in Normal and Hypoplastic Anemic W/Wv Mice. Blood 68:556,1986 (Supp.);

Leonard, J.P., May, W.S., Ihle, J.N., Pettit, G.R., Sharkis, S.J. Bryostatin 1 Mimics the Effect of IL-3 on Erythroid Precursors in Normal and Macrocytic Anemic W/Wv Mice. Blood 70:562, 1987 (Supp.);

Leonard, J.P. and Helfgott, D.C. Interleukin-6 Expression in Endotoxin-Resistant Mice.Clinical Research 41:250A, 1993;

Flasshove, M., Leonard, J.P., Ward M., Bank A., Moore M.A.S. Increased Resistance to Taxol for Peripheral Blood Progenitor Cells Following Transduction with an MDR-1 Encoding Retroviral Vector. Experimental Hematology 23:934, 1995;

Leonard, J.P., May, C., Gallardo, H., Rafii, S., Sadelain, M., Moore, M.A.S. Retroviral Transduction of Human Hematopoietic Progenitor Cells Using a Vector Encoding aCell Surface Marker (LNGFR) to Optimize Transgene Expression and Characterize Transduced Cell Populations. Blood 88 (S1):433a, 1996;

Kaminski, M.S., Zelenetz, A.D., Press, O., Saleh, M., Leonard, J.P., Fehrenbacher, L.,Stagg, R., Kroll, S., Tidmarsh, G., Knox, S., Vose, J. Multicenter, Phase III Study of Iodine-131 Tositumomab (Anti-B1 Antibody) For Chemotherapy-Refractory Low-Grade or Transformed Non-Hodgkin's Lymphoma. Blood 92 (S1):316a, 1998;

Leonard, J.P., Kaminski, M.S., Coleman, M., Kostakoglu, L., Estes, J., Tuck, M., Vallabhajosula, S., Kroll, S., Tidmarsh, G., Goldsmith, S.J., Wahl, R.L. Iodine 131 Labeled Anti-B1 Antibody (Tositumomab) in the Initial Treatment of Low-Grade Non-Hodgkin's Lymphoma. Cancer Investigation 18 (S1): 97-98, 1999;

Kostakoglu, L., Leonard, J.P., Coleman, M., Kuji I., Vallabhajosula, S., Golder, K., Goldsmith, S.J. Comparison of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) and Gallium-67 Scintigraphy in Staging and Follow-up of Patients with Lymphoma. Blood 94 (S1):84a, 1999;

Kostakoglu, L., Leonard, J.P., Coleman, M., Tidmarsh, G.F., Kroll, S.M., Bhatnagar, A.,Vallabhajosula S., Goldsmith, S.J. Extent of Disease Impacts the Effective Half-Life of Iodine I-131 Tositumomab in Non-Hodgkin's Lymphoma (NHL). Blood 94 (S1):90a, 1999;

Leonard, J.P., Coleman, M., Kostakoglu, L., Chadburn, A., Cesarman, E., Bhatnagar, A., Tidmarsh, G.F., Kroll, S.M., Goldsmith, S.J. Fludarabine Monophosphate Followed by Iodine I-131 Tositumomab for Untreated Low-Grade and Follicular Non-Hodgkin's Lymphoma (NHL). Blood 94 (S1):90a, 1999;

Gregory, S.A., Leonard, J.P., Coleman, M., Fehrenbacher, L., Bhatnagar, A., Magnuson, D., Kroll, S., Tidmarsh, G. BexxarTM (Tositumomab, Iodine I-131 Tositumomab) can be Safely Administered in Relapsed Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL) Patients after Prior Treatment with Rituximab: Initial Experience from the Expanded Access Study. Blood 94 (S1): 91a, 1999;

Leonard, J.P., Coleman, M., Schuster, M.W., Chadburn, A., Ely, S., Yagan, N., Sharkey, R.M., Hansen, H.J., Goldenberg, D.M. Epratuzumab, A New Anti-CD22, Humanized, Monoclonal Antibody for the Therapy of Non-Hodgkin's Lymphoma (NHL): Phase I/II Trial Results. Blood 94 (S1): 92a, 1999;

Coleman M., Leonard, J.P., Lee, C., Kaufmann, T.P., Schuster, M.W. The PEP-C(C3) Oral Combination Chemotherapy Regimen for Refractory/Relapsed Lymphoma:Daily Prednisone, Etoposide, Procarbazine and Cyclophosphamide. Blood 94 (S1): 94a,1999;

Coleman M., Leonard, J.P., Bayer, R.L., Gelfand, R.M., Kauffmann, T.P. DICE (Dexamethasone, Ifosfamide, Cisplatin, Etoposide) Infusional Chemotherapyfor Refractory/Relapsed Non-Hodgkin's Lymphoma. Blood 94 (S1): 523a, 1999;

Coleman M., Gelfand, R.M., Leonard, J.P. Combination Non-Myelosuppressive Therapy for Plasma Cell Myeloma: A Prelimary Report. Blood 94 (S2): 4604, 1999;

Leonard J.P., Coleman, M., Schuster, M.W., Feldman, E.J., Chadburn, A., Ely, S., Hansen, H.J., Wegener, W.A., Goldenberg, D.M. CD22-Directed Immunotherapy with Epratuzumab Results in Objective Responses With Minimal Toxicity. Presented at the International Conference on Advances in Cancer Immunotherapy, 2000;

Jong, R., Leonard, J.P., Coleman, M., Pan, L., Cesarman, E., Chadburn, A. Evaluation of Response to Therapy in Follicular Lymphoma (FL) by Morphology, Immunohistochemistry, Flow Cytometry, and PCR. Presented at the 2000 meeting of the United States and Canadian Academy of Pathology;

Coleman, M and Leonard, J.P. BLT-D (Biaxin, Low-Dose Thalidomide and Dexamethasone) Produces Consistent Responses in Myeloma and Waldenstrom's Macroglobulinemia. Proceedings of the American Society of Clinical Oncology, 19:9a, 2000;

Kostakoglu, L., Leonard, J.P., Coleman, M., Vallabhajosula, S., Spangler T., Goldsmith, S.J. Comparative Evaluation of FDG-PET in Staging of Patients with Lymphoma. Proceedings of the American Society of Clinical Oncology, 19:10a, 2000;

Leonard J.P., Coleman, M., Schuster, M.W., Feldman, E.J., Chadburn, A., Ely, S., Hansen, H.J., Wegener, W.A., Goldenberg, D.M. Immunotherapy of NHL with Epratuzumab (Anti-CD22 Monoclonal Antibody): Excellent Tolerability with Objective Responses. Proceedings of the American Society of Clinical Oncology, 19:17a, 2000;

Link, B.K., Wang, H., Byrd, J.C., Leonard, J.P., Davis, T.A., Hall, W.C., Turner, J.F., Rodrigues, G., Levitt, D., Weiner, G.J. Phase I Trial of Humanized 1D10 (Hu1D10) Monoclonal Antibody Targeting Class II Molecules in Patients with Relapsed Lymphoma. Proceedings of the American Society of Clinical Oncology, 19:24a, 2000;

Kostakoglu, L., Leonard, J.P., Coleman, M., Kuji, I., Vallabhajosula, S., Goldsmith, S.J. Evaluation of FDG-PET in the Detection of Bone Marrow Involvement in Lymphoma. Journal of Nuclear Medicine 41:71P, 2000;

Kostagoglu, L., Leonard, J.P., Coleman, M., Kroll, S.M., Bhatnagar, A., Vallabhajosula, S., Magnuson, D., Goldsmith, S.J. Patient-Specific Characteristics Correlate with the Effective Half-Life of I-131 Tositumomab Therapy in Non-Hodgkin's Lymphoma (NHL). Journal of Nuclear Medicine 41:79P, 2000;

Kostakoglu, L., Leonard, J.P., Coleman, M., Kuji, I., Vallabhajosula, S., Goldsmith, S.J. Comparison of FDG-PET and Ga-67 SPECT in the Staging of Lymphoma. Journal of Nuclear Medicine 41:118P, 2000;

Coleman, M., Leonard, J.P., Nahum, K., Michaeli, J. Non-Myelosuppressive Therapy with BLT-D (Biaxin, Low Dose Thalidomide and Dexamethasone) is Highly Active in Waldenstrom's Macroglobulinemia and Myeloma. Blood 96:167a, 2000;

Kostakoglu, L., Leonard, J.P., Kuji I., Coleman, M., Vallabhajosula, S., Goldsmith, S.J. Positron Emission Tomography has a Significantly Higher Sensitivity than Ga-67 SPECT at Initial Diagnosis in Low Grade Lymphoma. Blood 96: 328a, 2000;

Leonard, J.P., Coleman, M., Chadburn A., Matthews, J.C., Bayer, R., Schuster, M.W., Feldman, E.J., Juweid, M., Schuster, S.J., Wegener, W.A., Goldenberg, D.M. Epratuzumab (HLL2, Anti-CD22 Humanized Monoclonal Antibody) is an Active and Well-tolerated Therapy for Refractory/Relapsed Diffuse Large B-Cell Non-Hodgkin's Lymphoma (NHL). Blood 96: 578a, 2000;

Leonard, J.P., Zelenetz, A.D., Vose, J.M., Radford, J.A., Wahl, R.L., Rohatiner, A., Kroll, S., Stagg, R., Nadeau, K., Valente, N., Kaminski, M.S. Iodine I 131 Tositumomab for Patients with Low-Grade or Transformed Low-Grade NHL: Complete Response Data. Blood 96: 728a, 2000;

Kostakoglu, L., Leonard, J.P., Kuji, I., Coleman, M., Zoe, H., Goldsmith, S.J. Positron Emission Tomography After First Cycle of Chemotherapy Predicts Outcome At One Year in Aggressive Lymphoma and Hodgkin's Disease. Blood 96: 225b, 2000;

Gregory, S.A., Coleman, M., Ali A., O'Brien T.M., Subramanian, A., Kostakoglu, L., Goldsmith, S.A., Valente, N., Leonard, J.P. Efficacy and Safety of Bexxar in the Expanded Access Study: Interim Report From Two Institutions. Blood 96:238b, 2000;

Bayer, R., Feldman, E.J., Coleman, M., Roboz, G., Leonard, J.P., Michaeli, J., Schuster, M.W. Pentostatin Based Non-Myeloablative Conditioning Regimen in Patients with High-Risk Hematologic Malignancy. Blood 96:327b, 2000;

Link B.K., Wang H., Byrd J.C., Leonard J.P., Davis T.A., Flinn I., Hall W.C., Turner J.F., Levitt D., Weiner G.J. Phase I Study of Hu1D10 Monoclonal Antibody in Patients with B-Cell Lymphoma. Proceedings of the American Society of Clinical Oncology 20:284a, 2001;

Gockerman J., Gregory S., Harwood S., Kaminski M., Schenkein D., Fehrenbacher L., Dillman R., Fisher R., Takahashi G., Frenette G., Valente N., Leonard J.P. Interim Efficacy Results of BexxarTM in a Large Multicenter Expanded Access Study. Proceedings of the American Society of Clinical Oncology 20:285a, 2001;

Schenkein D.P., Leonard J.P., Harwood S., Gockerman J., Kaminski M., Jackson B., Dillman R., Fisher R., Takahashi G., Frenette G., Valente N., Gregory S. Interim Safety Results of BexxarTM in a Large Multicenter Expanded Access Study. Proceedings of the American Society of Clinical Oncology 20:285a, 2001;

Rohatiner A., Kaminski M., Leonard J.P., Vose J., Radford J., Wahl R., Zelenetz A., Nadeau K., Press O. BexxarTM Radioimmunotherapy is Efficacious in Non-Hodgkin's Lymphoma (NHL) Patients with Poor Prognostic Features. Proceedings of the American Society of Clinical Oncology 20:286a, 2001;

Zelenetz A., Wahl R., Kaminski M., Vose J., Kroll S., Leonard J.P. Individualized Patient Dosing Prevents Underdosing and Overdosing of Patients with Non-Hodgkin's Lymphoma. Proceedings of the American Society of Clinical Oncology 20:287a, 2001;

Leonard J.P., Coleman M., Kostakoglu L., Morris A., Gregory S., Link B., Kaminski M., Nadeau K., Valente N., Vallabhajosula S., Goldsmith S. BexxarTM (Iodine I-131 Tositumomab and Tositumomab) Can Be Administered Safely in Sequential Combination with Chemotherapy in Initial Treatment of Non-Hodgkin's Lymphoma (NHL). Proceedings of the American Society of Clinical Oncology 20:287a, 2001;

Goldsmith S.J., Kaminski M., Wahl R., Vose J., Zelenetz A., Kroll S., Clapp K., Leonard J.P. Dosimetry Optimizes Radiolabeled Antibody Dosing in Patients with Non-Hodgkin's Lymphoma. Proceedings of the American Society of Clinical Oncology 20:295a, 2001;

Frenette G., Gregory S., Gockerman J., Harwood S., Kaminski M., Schenkein D., Fehrenbacher L., Dillman R., Fisher R., Takahashi G., Valente N., Leonard, J.P. Efficacy and Safety of BexxarTM is Not Affected by the Dosing Enterval. Proceedings of the American Society of Clinical Oncology 20:296a, 2001;

Kostakoglu L., Leonard J.P., Coleman M., Zoe H., Vallabhajosula S., Fiore J.M., Dreher D., Hack S., Goldsmith S.J. Prediction of Response to Therapy Using Early F-18 Fluorodeoxyglucose Imaging (FDG-PET) in Patients Undergoing I-131 Tositumomab Therapy. Proceedings of the American Society of Clinical Oncology 20:237b, 2001;

Hajjar G, Sharkey RM, Burton J, Schuster S, Czuczman M, Lamonica D, Chatal J, Alavi A, Stadtmauer E, Leonard JP, Coleman M, Plutchock J, Brenner AI, Goldenberg DM. Interim Results of a Phase I/II Radioimmunotherapy Trial in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) Patients Given 90Y-Labeled Anti-CD22 Humanized Monoclonal Antibody, Epratuzumab. Blood 98:2560, 2001;

Link BK, Kahl B, Czuczman M, Powell BL, Bartlett N, Leonard JP, Ansell S, Porcu P, Byrd JC, Lazarus HM, Flinn I, Jones GJ, Levitt D, Hall WC, Weiner GJ. A Phase II Study of RemitogenTM (Hu1D10), a Humanized Monoclonal Antibody In Patients with Relapsed or Refractory Follicular, Small Lymphocytic, or Marginal Zone/MALT B-Cell Lymphoma. Blood 98: 2540,2001;

Leonard JP, Frenette G, Dillman RO, Gregory SA. Interim Safety and Efficacy Results of BexxarTM in a Large Multicenter Expanded Access Study. Blood 98:559, 2001;

Zelenetz AD, Wahl R, Leonard JP, Gregory SA, Clapp K, Kaminski M. Individualized Patient Dosing with Radioimmunotherapy Prevents Under- and Over-Dosing of Patients and Is Associated with Tolerable and Predictable Hematologic Toxicity in Patients with Non-Hodgkin's Lymphoma (NHL). Blood 98:565, 2001;

Leonard JP, Zelenetz AD, Vose JM, Coleman M, Clapp KJ, Kaminski MS. BexxarTM (Tositumomab and Iodine I 131 Tositumomab) Results in Durable Long-Term Responses in Patients with Poor Prognisis, Multiply Relapsed (Rel), and Refractory (Ref) Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL). Blood 98:2527, 2001;

Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Hack S, Kroll SM, Tidmarsh G, Vallabhajosula S, Goldsmith SJ. Triple Modality Therapy for Follicular Low-Grade Lymphoma: Initial Treatment with Fludarabine Followed By BexxarTM (Tositumomab and Iodine I 131 Tositumomab). Blood 98:3505, 2001;

Leonard JP, Coleman M, Matthews JC, Fiore JM, Dosik A, Kapushoc H, Kin E, Cesano A, Wegener WA, Goldenberg DM. Combination Monoclonal Antibody Therapy for Lymphoma: Treatment with Epratuzumab (Anti-CD22) and Rituximab (Anti-20) is Well Tolerated. Blood 98:3506, 2001;